New Drug ApprovalAmgen Wins EU Approval for IMDYLLTRA in Relapsed ES-SCLC Amgen Wins EU Approval for IMDYLLTRA in Relapsed ES-SCLC Read Post »
Health Tidings Mergers & AcquisitionsServier Acquires Edgewise Muscular Dystrophy Business for Up to $2.65 Billi... Servier Acquires Edgewise Muscular Dystrophy Business for Up to $2.65 Billi... Read Post »
Clinical TrialsIdorsia Reports Positive High-Dose Phase 1 Data for C. difficile Vaccine Idorsia Reports Positive High-Dose Phase 1 Data for C. difficile Vaccine Read Post »
Clinical TrialsPersonalized mRNA Vaccine Plus KEYTRUDA Maintains Strong Melanoma Outcomes Personalized mRNA Vaccine Plus KEYTRUDA Maintains Strong Melanoma Outcomes Read Post »
Clinical TrialsIdorsia Unveils New Phase 3 Evidence for Aprocitentan’s Renal Benefits Idorsia Unveils New Phase 3 Evidence for Aprocitentan’s Renal Benefits Read Post »
Mergers & AcquisitionsAgios Lands Global Cevidoplenib Rights in Rare Hematology Push Agios Lands Global Cevidoplenib Rights in Rare Hematology Push Read Post »
Clinical TrialsNovartis Reports Strong Three-Year Scemblix Results in Newly Diagnosed CML Novartis Reports Strong Three-Year Scemblix Results in Newly Diagnosed CML Read Post »
New Drug ApprovalShionogi Wins FDA Approval for First Oral XOCOVA to Prevent COVID-19 After ... Shionogi Wins FDA Approval for First Oral XOCOVA to Prevent COVID-19 After ... Read Post »
Clinical TrialsBioNTech and BMS Report Strong Phase 2 Activity for Pumitamig in NSCLC BioNTech and BMS Report Strong Phase 2 Activity for Pumitamig in NSCLC Read Post »
Clinical TrialsReplimune’s RP2 Shows Durable Responses in Advanced Solid Tumors Replimune’s RP2 Shows Durable Responses in Advanced Solid Tumors Read Post »
Health TidingsUCB, Biogen Report Positive PHOENYCS GO Results in SLE UCB, Biogen Report Positive PHOENYCS GO Results in SLE Read Post »
Health TidingsPfizer’s BRAFTOVI Cuts Progression Risk by 56% in BRAF V600E mCRC Pfizer’s BRAFTOVI Cuts Progression Risk by 56% in BRAF V600E mCRC Read Post »
Health TidingsRevMed’s Daraxonrasib Cuts Death Risk by 60% in PDAC RevMed’s Daraxonrasib Cuts Death Risk by 60% in PDAC Read Post »
Clinical TrialsASCO 2026: Novartis’s New PSMAddition Analysis Supports Broad Pluvicto Us... ASCO 2026: Novartis’s New PSMAddition Analysis Supports Broad Pluvicto Us... Read Post »
Clinical TrialsLilly’s Retevmo Reduces Recurrence Risk by 83% in RET-Positive NSCLC Lilly’s Retevmo Reduces Recurrence Risk by 83% in RET-Positive NSCLC Read Post »
Clinical TrialsAkeso’s Ivonescimab Cuts Risk of Death by 34% in Phase 3 Squamous NSCLC T... Akeso’s Ivonescimab Cuts Risk of Death by 34% in Phase 3 Squamous NSCLC T... Read Post »
